U.S. flag

An official website of the United States government

NM_007194.4(CHEK2):c.1169A>G (p.Tyr390Cys) AND Hereditary cancer-predisposing syndrome

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Nov 3, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000566309.7

Allele description [Variation Report for NM_007194.4(CHEK2):c.1169A>G (p.Tyr390Cys)]

NM_007194.4(CHEK2):c.1169A>G (p.Tyr390Cys)

Gene:
CHEK2:checkpoint kinase 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
22q12.1
Genomic location:
Preferred name:
NM_007194.4(CHEK2):c.1169A>G (p.Tyr390Cys)
HGVS:
  • NC_000022.11:g.28695800T>C
  • NG_008150.2:g.51067A>G
  • NM_001005735.2:c.1298A>G
  • NM_001257387.2:c.506A>G
  • NM_001349956.2:c.968A>G
  • NM_007194.4:c.1169A>GMANE SELECT
  • NM_145862.2:c.1082A>G
  • NP_001005735.1:p.Tyr433Cys
  • NP_001244316.1:p.Tyr169Cys
  • NP_001336885.1:p.Tyr323Cys
  • NP_009125.1:p.Tyr390Cys
  • NP_665861.1:p.Tyr361Cys
  • LRG_302t1:c.1169A>G
  • LRG_302:g.51067A>G
  • LRG_302p1:p.Tyr390Cys
  • NC_000022.10:g.29091788T>C
  • NG_008150.1:g.51035A>G
  • NM_007194.3:c.1169A>G
Protein change:
Y169C
Links:
dbSNP: rs200928781
NCBI 1000 Genomes Browser:
rs200928781
Molecular consequence:
  • NM_001005735.2:c.1298A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001257387.2:c.506A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349956.2:c.968A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_007194.4:c.1169A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_145862.2:c.1082A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000665261Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Likely pathogenic
(Nov 3, 2023)
germlineclinical testing

PubMed (7)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Structural basis for peptide binding in protein kinase A. Role of glutamic acid 203 and tyrosine 204 in the peptide-positioning loop.

Moore MJ, Adams JA, Taylor SS.

J Biol Chem. 2003 Mar 21;278(12):10613-8. Epub 2002 Dec 23.

PubMed [citation]
PMID:
12499371

Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Lountos GT, Jobson AG, Tropea JE, Self CR, Zhang G, Pommier Y, Shoemaker RH, Waugh DS.

J Struct Biol. 2011 Dec;176(3):292-301. doi: 10.1016/j.jsb.2011.09.008. Epub 2011 Sep 22.

PubMed [citation]
PMID:
21963792
PMCID:
PMC3210331
See all PubMed Citations (7)

Details of each submission

From Ambry Genetics, SCV000665261.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (7)

Description

The p.Y390C variant (also known as c.1169A>G), located in coding exon 10 of the CHEK2 gene, results from an A to G substitution at nucleotide position 1169. The tyrosine at codon 390 is replaced by cysteine, an amino acid with highly dissimilar properties. In one study, this variant was reported in 2/60,466 breast cancer cases and in 0/53,461 controls (Dorling et al. N Engl J Med. 2021 02;384:428-439). This alteration was also detected in 3/95 Turkish women with breast or ovarian cancer who were diagnosed before 50 years of age and known to not carry mutations in the BRCA1, BRCA2, and PALB2 genes and in 1/60 controls without breast cancer and without a family history of breast cancer (Aksoy F et al. Hum Hered, 2022 Jan). This alteration occurs at a statistically increased frequency in Chinese breast cancer patients compared to an ethnically- and age-matched control population (Wang N et al. Oncogene, 2015 Oct;34:5198-205). This variant is unable to efficiently phosphorylate p53 and CDC25A and CHEK2-knockdown cells rescued with this variant also show weaker expression of p53 transcriptional targets. These defects may directly contribute to the observed inability of this variant to restore sensitivity to DNA damaging agents; increased cell survival; decreased rates of apoptosis; and deregulation of the cell cycle after DNA damage, each of which were similar to cells which had CHEK2-knockdown in contrast to cells rescued with wildtype CHEK2 (Wang N et al. Oncogene, 2015 Oct;34:5198-205; Luo L et al. Med. Sci. Monit., 2018 May;24:3176-3183). This alteration was also reported as damaging in an mES cell-based assay of CHEK2 activity (Boonen RACM et al. Cancer Res, 2022 Feb;82:615-631). Based on internal structural assessment, this alteration disrupts a highly conserved motif in kinases that is necessary for positioning the activation loop (Lountos GT et al. J. Struct. Biol., 2011 Dec;176:292-301; Moore MJ et al. J. Biol. Chem., 2003 Mar;278:10613-8; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024